Perceptive Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.3M Buy
149,950
+1,050
+0.7% +$181K 0.5% 44
2025
Q4
$27.2M Hold
148,900
0.48% 52
2025
Q3
$18.1M Sell
148,900
-49,634
-25% -$5.59M 0.52% 47
2025
Q2
$20.7M Sell
198,534
-156,573
-44% -$16.6M 0.77% 36
2025
Q1
$41.4M Sell
355,107
-308,967
-47% -$35.2M 1.46% 20
2024
Q4
$56.2M Sell
664,074
-118,770
-15% -$10.9M 1.55% 20
2024
Q3
$70.4M Buy
782,844
+323,733
+71% +$28.3M 1.49% 19
2024
Q2
$37M Sell
459,111
-646,230
-58% -$47.8M 0.89% 32
2024
Q1
$88.2M Buy
1,105,341
+67,322
+6% +$5.65M 1.54% 21
2023
Q4
$82.6M Buy
1,038,019
+556,370
+116% +$37.2M 1.84% 12
2023
Q3
$33.7M Buy
481,649
+210,156
+77% +$15.7M 1.12% 28
2023
Q2
$19.5M Buy
+271,493
New +$20M 0.56% 51
2022
Q1
Sell
-80,420
Closed -$3.04M 137
2021
Q4
$3.04M Hold
80,420
0.05% 129
2021
Q3
$2.65M Sell
80,420
-473,488
-85% -$18.5M 0.04% 129
2021
Q2
$37.4M Buy
+553,908
New +$33.2M 0.48% 52
2020
Q3
Sell
-50,000
Closed -$4.11M 132
2020
Q2
$4.11M Buy
+50,000
New +$3.85M 0.07% 97
2019
Q4
Sell
-53,879
Closed -$1.09M 116
2019
Q3
$1.09M Hold
53,879
0.03% 87
2019
Q2
$1.39M Hold
53,879
0.03% 88
2019
Q1
$767K Buy
+53,879
New +$500K 0.02% 88

Other funds holding AXSM

Perceptive Advisors's AXSM Position: Q1 2026 in Review

Perceptive Advisors increased its Axsome Therapeutics (AXSM) stake by 0.71% in Q1 2026, buying an estimated $181K and bringing the position to 149,950 shares worth $25.3M. The position accounts for 0.5% of the portfolio, ranked #44.

Perceptive Advisors first reported a position in AXSM in Q1 2019 and has held it in 19 quarters since. The position peaked at $88.2M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Perceptive Advisors held 149,950 shares of Axsome Therapeutics worth $25.3M as of Q1 2026.
  • Perceptive Advisors bought 1,050 Axsome Therapeutics shares in Q1 2026, an estimated $181K.
  • Axsome Therapeutics made up 0.5% of Perceptive Advisors's portfolio in Q1 2026, its #44 holding.
  • Perceptive Advisors first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 19 quarters since.
  • Perceptive Advisors's Axsome Therapeutics position peaked at $88.2M in Q1 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.